Posted in Library Resources, Publications, scholarly literature

Staff Publications: October 2016

1. Abbosh PH, Rosenberg JE, Plimack ER. Circulating biomarkers to guide systemic therapy for urothelial carcinoma. Urologic oncology. 2016 PMID: 27751785.

2. Ajani JA, D’Amico TA, Almhanna K, et al. Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2016;14(10):1286-1312.

3. Andrake MD, Skalka AM. Retroviral Integrase: Then and Now. Annual review of virology. 2015;2(1):241-264 PMID: 26958915, PMC4810031.

4. Barbosa Vendramini-Costa D, Francescone R, Posocco D, et al. Anti-inflammatory natural product goniothalamin reduces colitis-associated and sporadic colorectal tumorigenesis. Carcinogenesis. 2016 PMID: 27797827

5. Beitler JJ, Quon H, Jones CU, et al. ACR Appropriateness Criteria (R) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2016;38(9):1299-1309.

6. Bober SL, Reese JB, Barbera L, et al. How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer. Current opinion in supportive and palliative care. 2016;10(1):44-54 PMID: 26716390, PMC4984532.

7. Bobrov E, Skobeleva N, Restifo D, et al. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget. 2016 PMID: 27779106.

8. Capo-chichi CD, Aguida B, Chabi NW, et al. Lamin A/C deficiency is an independent risk factor for cervical cancer. Cellular oncology (Dordrecht). 2016;39(1):59-68 PMID: 26537870.

9. Carlson RW, McClure JS. Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA oncology. 2016 PMID: 27787555.

10. Chan JK, Java JJ, Fuh K, et al. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients – An analysis of NRG oncology/gynecologic oncology group trials. Gynecologic oncology. 2016 PMID: 27771168.

11. Choi YB, Shembade N, Parvatiyar K, Balachandran S, Harhaj EW. TAX1BP1 restrains virus-induced apoptosis by facilitating Itch-mediated degradation of the mitochondrial adaptor MAVS. Molecular and cellular biology. 2016 PMID: 27736772.

12. Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 PMID: 27169994>

13. Churilla TM, Egleston B, Bleicher R, Dong Y, Meyer J, Anderson P. Disparities in the Local Management of Breast Cancer in the US according to Health Insurance Status. The breast journal. 2016 PMID: 27797159.

14. Churilla TM, Egleston BL, Murphy CT, et al. Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast cancer research and treatment. 2016 PMID: 27766452.

15. Clark PE, Spiess PE, Agarwal N, et al. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(10):1213-1224 PMID: 27697976.

16. Daly MB, Pilarski R, Axilbund JE, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(2):153-162 PMID: 26850485.

17. Davis BM, Rall GF, Schnell MJ. Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask). Annual review of virology. 2015;2(1):451-471 PMID: 26958924.

18. Devarajan K, Cheung VCK. A Quasi-Likelihood Approach to Nonnegative Matrix Factorization. Neural Computation. 2016;28(8):1663-1693.

19. Doss M. Disavowing the ALARA concept in pediatric imaging. Pediatric radiology. 2016:1.

20. Duivenvoorden WC, Daneshmand S, Canter D, et al. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. The Journal of urology. 2016 PMID: 27312316.

21. Duong-Ly KC, Devarajan K, Liang S, et al. Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell reports. 2016;14(4):772-781 PMID: 26776524, PMC4740242.

22. El-Deiry WS, Vijayvergia N, Xiu J, et al. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer biology & therapy. 2015;16(12):1726-1737 PMID: 26553611, PMC4847814.

23. Friedant AJ, Handorf EA, Su S, Scott WJ. Minimally Invasive versus Open Thymectomy for Thymic Malignancies: Systematic Review and Meta-Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(1):30-38 PMID: 26762737.

24. Gaponova AV, Nikonova AS, Deneka AY, et al. A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer. Clinical Cancer Research. 2016;22(20):5120-5129.

25. Geynisman DM, Handorf E, Wong YN, et al. Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer medicine. 2016;5(2):192-199 PMID: 26679712, PMC4735777.

26. Gonzalez BD, Manne SL, Stapleton J, et al. Quality of life trajectories after diagnosis of gynecologic cancer: a theoretically based approach. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2016 PMID: 27757706.

27. Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN Guidelines Insights Breast Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 2015;13(12):1475-1485 PMID: 26656517.

28. Gregory KA. Easy as ABC: How Staff Nurses Transformed Unit Culture to Assess and Manage Delirium in the Intensive Care Unit. Critical care nurse. 2016;36(5):73-76 PMID: 27694361.

29. Guo J, Zinner R, Zaorsky NG, Guo W, Lu B. Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. Journal of thoracic disease. 2016;8(9):E1028-e1031 PMID: 27747054.

30. Gupta S, Wang L, Kruger WD. Betaine supplementation is less effective than methionine restriction in correcting phenotypes of CBS deficient mice. Journal of inherited metabolic disease. 2016;39(1):39-46 PMID: 26231230, PMC4784539.

31. Guttmann DM, Li H, Sevak P, et al. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2016;26(1):141-148 PMID: 26509850.

32. Hamdi Y, Soucy P, Kuchenbaeker KB, et al. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast cancer research and treatment. 2016 PMID: 27796716.

33. Haughey BH, Sinha P, Kallogjeri D, et al. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral oncology. 2016;62:11-19.

34. Hossain NM, Chapuis AG, Walter RB. T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies. Current Hematologic Malignancy Reports. 2016;11(4):311-317.

35. Hossain NM, Klumpp T, Ulicny J, et al. Donor Lymphocyte Infusion in Hematologic Malignancies–Good to be Fresh? Clinical lymphoma, myeloma & leukemia. 2016;16(2):111-115 PMID: 26632076.

36. Hudson SV, Ohman-Strickland PA, Bator A, et al. Breast and prostate cancer survivors’ experiences of patient-centered cancer follow-up care from primary care physicians and oncologists. Journal of Cancer Survivorship. 2016;10(5):906-914.

37. Hui SKA, Miller SM, Hazuda L, Engelman K, Ellerbeck EF. Novel Method for Recruiting Representative At-Risk Individuals into Cancer Prevention Trials: Online Health Risk Assessment in Employee Wellness Programs. Journal of Cancer Education. 2016;31(3):421-429.

38. Ingram JP, Brodsky IE, Balachandran S. Interferon-gamma in Salmonella pathogenesis: New tricks for an old dog. Cytokine. 2016 PMID: 27773552.

39. Jaffe EK. The Remarkable Character of Porphobilinogen Synthase. Accounts of chemical research. 2016 PMID: 27783504.

40. Jiang W, Dulaimi E, Devarajan K, et al. Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. PloS one. 2016;11(10):e0164554 PMID: 27764136.

41. Jin C, Qin T, Barton MC, Jelinek J, Issa JP. Minimal role of base excision repair in TET-induced global DNA demethylation in HEK293T cells. Epigenetics. 2015;10(11):1006-1013 PMID: 26440216, PMC4844212.

42. Jin L, Price RA, Wang L, Meyer J, Fan JJ, Ma CM. Dosimetric and delivery efficiency investigation for treating hepatic lesions with a MLC-equipped robotic radiosurgery-radiotherapy combined system. Medical physics. 2016;43(2):727-733 PMID: 26843236.

43. Katz MHG, Shi Q, Ahmad SA, et al. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101. Jama Surgery. 2016;151(8).
44. Kniazeva E, Hardy AN, Boukaidi SA, Woodruff TK, Jeruss JS, Shea LD. Primordial Follicle Transplantation within Designer Biomaterial Grafts Produce Live Births in a Mouse Infertility Model. Scientific reports. 2015;5:17709 PMID: 26633657, PMC4668556.

45. Kutikov A, Woo HH, Catto JW. Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors. European urology. 2016;69(2):183-185 PMID: 26443429.

46. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 2016 PMID: 27745820.

47. Lango MN, Handorf E, Arjmand E. The geographic distribution of the otolaryngology workforce in the United States. The Laryngoscope. 2016 PMID: 27774588.

48. Leachman BK, Galloway TJ. The Role for Radiation Therapy in the Management of Sarcoma. Surgical Clinics of North America. 2016;96(5):1127-1139.

49. Leichman L, Groshen S, O’Neil BH, et al. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. The oncologist. 2016;21(2):172-177 PMID: 26786262, PMC4746089.

50. Li P, Wong YN, Armstrong K, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer medicine. 2016;5(2):169-181 PMID: 26645975, PMC4735783.

51. Manne SL, Topham N, Kirstein L, et al. Attitudes and Decisional Conflict Regarding Breast Reconstruction Among Breast Cancer Patients. Cancer nursing. 2016;36(6):427-436 PMID: 26780376, PMC4947023.

52. Marks EI, Tan C, Zhang J, et al. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer biology & therapy. 2015;16(12):1710-1719 PMID: 26561209, PMC4847811.

53. McComb BL, Munden RF, Duan FH, Jain AA, Tuite C, Chiles C. Normative reference values of thoracic aortic diameter in American College of Radiology Imaging Network (ACRIN 6654) arm of National Lung Screening Trial. Clinical Imaging. 2016;40(5):936-943.

54. Michael JV, Wurtzel JG, Goldfinger LE. Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment. Anticancer research. 2016;36(10):5053-5061 PMID: 27798864.

55. Mizukami T, Sakuma Y, Maki K. Statistical Mechanical Model for pH-Induced Protein Folding: Application to Apomyoglobin. Journal of Physical Chemistry B. 2016;120(34):8970-8986.

56. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(1):19-30 PMID: 26733552.

57. Monteith JA, Mellert H, Sammons MA, et al. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. Molecular Oncology. 2016;10(8):1207-1220.

58. Necchi A, Sonpavde G, Lo Vullo S, et al. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European urology. 2016 PMID: 27726966.

59. Peng S, Zhou P, He W, Liao M, Chen L, Ma CM. Treatment of hepatic tumors by thermal versus mechanical effects of pulsed high intensity focused ultrasound in vivo. Physics in Medicine and Biology. 2016;61(18):6754-6769.

60. Ramakodi MP, Kulathinal RJ, Chung Y, Serebriiskii I, Liu JC, Ragin CC. Ancestral-derived effects on the mutational landscape of laryngeal cancer. Genomics. 2016;107(2-3):76-82 PMID: 26721311, PMC4761303.

61. Ream E, Gargaro G, Barsevick A, Richardson A. Management of cancer-related fatigue during chemotherapy through telephone motivational interviewing: modeling and randomized exploratory trial. Patient education and counseling. 2015;98(2):199-206 PMID: 25468398.

62. Reese JB, Haythornthwaite JA. Importance of sexuality in colorectal cancer: predictors, changes, and response to an intimacy enhancement intervention. Supportive Care in Cancer. 2016;24(10):4309-4317.

63. Rice TW, Apperson-Hansen C, DiPaola LM, et al. Worldwide Esophageal Cancer Collaboration: clinical staging data. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2016;29(7):707-714 PMID: 27731549.

64. Rice TW, Chen LQ, Hofstetter WL, et al. Worldwide Esophageal Cancer Collaboration: pathologic staging data. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2016;29(7):724-733 PMID: 27731547.

65. Rice TW, Lerut TE, Orringer MB, et al. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2016;29(7):715-723 PMID: 27731548.

66. Ristau BT, Smaldone MC. Difference of opinion – Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: No. International braz j urol : official journal of the Brazilian Society of Urology. 2016;42(5):880-882 PMID: 27716457.

67. Russo J. Reproductive history and breast cancer prevention. Hormone Molecular Biology and Clinical Investigation. 2016;27(1):3-10.

68. Scharpf J, Tuttle M, Wong R, et al. Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society consensus statement: AHNS consensus statement. Head & neck. 2016 PMID: 27717219.

69. Schuetze SM, Bolejack V, Choy E, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2016 PMID: 27696380.

70. Shah JJ, Jakubowiak AJ, O’Connor OA, et al. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(1):34-43 PMID: 26561559.

71. Shemesh A, Kugel A, Steiner N, et al. NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint. Oncotarget. 2016 PMID: 27765926.

72. Silvestri V, Barrowdale D, Mulligan AM, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast cancer research : BCR. 2016;18(1):15 PMID: 26857456, PMC4746828.

73. Smaglo BG, Tesfaye A, Halfdanarson TR, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget. 2015;6(41):43594-43604 PMID: 26498363, PMC4791253.

74. Smith MR, Hong F, Li H, et al. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia. 2016 PMID: 27780968.

75. Speen AM, Kim HH, Bauer RN, et al. Ozone-derived Oxysterols Affect Liver X Receptor (LXR) Signaling: A Potential Role for Lipid-Protein Adducts. The Journal of biological chemistry. 2016 PMID: 27703007.

76. Stinchcombe TE, Borghaei H, Barker SS, Treat JA, Obasaju C. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer. Clinical lung cancer. 2016;17(1):1-9 PMID: 26340853.

77. Studitsky VM, Nizovtseva EV, Shaytan AK, Luse DS. Nucleosomal Barrier to Transcription: Structural Determinants and Changes in Chromatin Structure. Biochemistry & molecular biology journal. 2016;2(2) PMID: 27754494, PMC5041593.

78. Swisher SG, Moughan J, Komaki RU, et al. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 PMID: 27729298.

79. Tanaka K, Whelan KA, Chandramouleeswaran PM, et al. ALDH2 modulates autophagy flux to regulate acetaldehyde-mediated toxicity thresholds. American Journal of Cancer Research. 2016;6(4):781-796.

80. Terry MB, Phillips KA, Daly MB, et al. Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). International Journal of Epidemiology. 2016;45(3):683-692.

81. Thapa RJ, Ingram JP, Ragan KB, et al. DAI Senses Influenza A Virus Genomic RNA and Activates RIPK3-Dependent Cell Death. Cell host & microbe. 2016 PMID: 27746097.
82. Thomas C, Ji Y, Lodhi N, et al. Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo. EBioMedicine. 2016 PMID: 27727003.

83. Travis WD, Asamura H, Bankier AA, et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology. 2016;11(8):1204-1223.

84. Tsueng G, Good BM, Ping PP, et al. Gene Wild Reviews-Raising the quality and accessibility of information about the human genome. Gene. 2016;592(2):235-2.

85. Valieva ME, Feofanov AV, Studitsky VM. Histone chaperones: Variety and functions. Moscow University Biological Sciences Bulletin. 2016;71(3):165-169.

86. Vijayvergia N, Cohen SJ. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? Journal of gastrointestinal oncology. 2016;7(5):727-737 PMID: 27747087.

87. Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, et al. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Oncotarget. 2016 PMID: 27740936.

88. Wang EH, Yu JB, Abouassally R, et al. Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology. 2016;95:88-94.

89. Wang M, Devarajan K, Singal AG, et al. The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. Cancer prevention research (Philadelphia, Pa). 2016;9(2):172-179 PMID: 26712941, PMC4740237.

90. Weinberg Md DS, Barkun A, Turner BJ. Colorectal Cancer Screening in the United States: What Is the Best FIT? Annals of internal medicine. 2016 PMID: 27776358.

91. Wells G, Chernoff J, Gilligan JP, Krause DS. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016;27(1):13-19 PMID: 26438308, PMC4715844.

92. Wickstrom L, Deng N, He P, et al. Parameterization of an effective potential for protein-ligand binding from host-guest affinity data. Journal of molecular recognition : JMR. 2016;29(1):10-21 PMID: 26256816, PMC4715590.

93. Winn JS, Baker MG, Fanous IS, Slack-Davis JK, Atkins KA, Dillon PM. Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival. Oncology. 2016;91(3):135-142.

94. Wong YN, Roach N, Meropol NJ. Addressing Patients’ Priorities as a Strategy to Improve Value. The oncologist. 2016 PMID: 27742905.

95. Xiao C, Zhang Q, Nguyen-Tan PF, et al. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. International journal of radiation oncology, biology, physics. 2016 PMID: 27727063.

96. Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. European Journal of Haematology. 2016;97(2):108-120.

97. Zaorsky NG, Churilla TM, Ruth K, et al. Men’s health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer. The American journal of clinical nutrition. 2016 PMID: 27797706.

98. Zaorsky NG, Shaikh T, Ruth K, et al. Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy. Clinical genitourinary cancer. 2016 PMID: 27789181.

99. Zhao S, Torres A, Henry RA, et al. ATP-Citrate Lyase Controls a Glucose-to-Acetate Metabolic Switch. Cell reports. 2016;17(4):1037-1052 PMID: 27760311.

100. Zhou Z, Rademaker AW, Gordon LI, et al. High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(10):1274-1281 PMID: 27697981.

101. Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncology. 2016;12(19):2227-2242.

102. Zijoo R, Olszanski AJ, Weinberg DS. Biomarkers and stage II colorectal cancer therapy. Translational Cancer Research. 2016;5:S84-S86.

103. Zou ZW, Ma C, Medoro L, et al. LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing sidepopulation stem-like cancer cells. Oncotarget. 2016;7(38):61741-61754.

Posted in Library Resources, Publications, scholarly literature, writing

Staff Publications: September 2016

1.    Adams DL, Alpaugh RK, Tsai S, Tang CM, Stefansson S. Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining. Sci Rep. 2016;6:33488. PMID: 27647345 PMCID: PMC5028835.

2.    Allen JE, Kline CL, Prabhu VV, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 PMID: 27602582.

3.    Atretkhany KN, Drutskaya MS, Nedospasov SA, Grivennikov SI, Kuprash DV. Chemokines, cytokines and exosomes help tumors to shape inflammatory
microenvironment. Pharmacol Ther. 2016 PMID: 27613100.

4.    Avkshtol V, Doss M, Devarajan K, et al. Using Metabolic Tumor Velocity to Preoperatively Predict the Neoadjuvant Rectal Score. Int J Radiat Oncol Biol Phys. 2016;96(2S):E206-E207. PMID: 27674061.

5.    Bass SB, Wolak C, Greener J, et al. Using perceptual mapping methods to understand gender differences in perceived barriers and benefits of clinical research participation in urban minority HIV+ patients. AIDS Care. 2016;28(4):528-536. PMID: 26572215.

6.    Bassi DE, Zhang J, Renner C, Klein-Szanto AJ. Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth. Mol Carcinog. 2016 PMID: 27584082.

7.    Bauman JR, Piotrowska Z, Muzikansky A, et al. End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. J Palliat Med. 2016 PMID: 27626514.

8.    Bellacosa A, Chernoff J, Testa JR. Alfred G. Knudson (1922-2016) Obituary. Cell. 2016;166(4):785-786. WOS:000382258700001.

9.    Borghaei H, Brahmer J, Horn L, et al. P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy. J Thorac Oncol. 2016;11(10S):S237-S238. PMID: 27676569.

10.    Buscariollo D, Cronin A, Bleicher RJ, et al. Association Between the 21-Gene Recurrence Score and Isolated Local-Regional Recurrence in Hormone Receptor-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2016;96(2S):E13. PMID: 27673854.

11.    Cagney DN, Van Dijk KR, Horvath MC, et al. Cortical Structural Changes in Patients Receiving Whole-Brain Radiation Therapy (WBRT). Int J Radiat Oncol Biol Phys. 2016;96(2S):E71-E72. PMID: 27675426.

12.    Chen L, Cvetkovic D, Wang B, Gupta R, Ma CM. Management of Prostate Cancer Using Magnetic Resonance Guided Pulsed Focused Ultrasound-Mediated Targeted Chemotherapeutic Agent Delivery. Int J Radiat Oncol Biol Phys. 2016;96(2S):E260. PMID: 27674203.

13.    Chow LQ, Haddad R, Gupta S, et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 PMID: 27646946.

14.    Churilla TM, Egleston BL, Murphy CT, et al. Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016 PMID: 27640196.

15.    Churilla TM, Handorf E, Soffietti R, et al. Does Whole-Brain Radiation Therapy for Oligometastatic Brain Metastases Translate Into a Survival Benefit for Patients With a Limited Competing Risk From Extracranial Disease? A Secondary Analysis of EORTC 22952-26001. Int J Radiat Oncol Biol Phys. 2016;96(2S):S56-S57. PMID: 27675960.

16.    Corradetti C, Jog NR, Gallucci S, Madaio M, Balachandran S, Caricchio R. Immune-Mediated Nephropathy and Systemic Autoimmunity in Mice Does Not Require Receptor Interacting Protein Kinase 3 (RIPK3). PLoS One. 2016;11(9):e0163611. PMID: 27669412.

17.    Dhawan I, Li T, Fundakowski C, et al. Is a Focally Positive Margin During Glossectomy an Indication for Adjuvant Radiation If the Margin Is Re-Resected During the Same Operation? Int J Radiat Oncol Biol Phys. 2016;96(2S):E349-E350. PMID: 27674448.

18.    Dong Y, Li T, Churilla TM, et al. Long-Term Toxicities in Survivors of Radiation Treatment for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016;96(2S):E394. PMID: 27674573.

19.    Dziemianowicz M, Murphy CT, Devarajan K, et al. Evaluating the Impact of Node-Specific Growth in Patients With Node-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2016;96(2S):E368-E369. PMID: 27674500.

20.    El-Deiry WS. p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy. Cancer Res. 2016;76(18):5189-5191. PMID: 27635040 PMCID: PMC5028108.
21.    Escalante DA, Wang H, Fundakowski CE. Fusion proteins in head and neck neoplasms: Clinical implications, genetics, and future directions for targeting. Cancer Biol Ther. 2016:1-8. PMID: 27636353.

22.    Fareed MM, Churilla TM, Galloway TJ. Impact of Primary Tumor-Specific Growth Rate on Treatment Failure for Non-Oropharyngeal Head and Neck Cancers. Int J Radiat Oncol Biol Phys. 2016;96(2S):E390. PMID: 27674561.

23.    Feitelson MA, Arzumanyan A, Kulathinal RJ, et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015;35 Suppl:S25-54. PMID: 25892662 PMCID: PMC4898971.

24.    Flynn KE, Lin L, Bruner DW, et al. Sexual Satisfaction and the Importance of Sexual Health to Quality of Life Throughout the Life Course of U.S. Adults. J Sex Med. 2016 PMID: 27671968.

25.    Gray PN, Vuong H, Tsai P, et al. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget. 2016 PMID: 27626691.

26.    Hawken SR, Krishnan NK, Ambani SN, et al. Effect of delayed resection after initial surveillance and tumor growth rate on final surgical pathology in patients with small renal masses (SRMs). Urol Oncol. 2016 PMID: 27687544.

27.    Heckman CJ, Kloss JD, Feskanich D, Culnan E, Schernhammer ES. Associations among rotating night shift work, sleep and skin cancer in Nurses’ Health Study II participants. Occup Environ Med. 2016 PMID: 27663986.

28.    Hoffman JP, Reddy SS. Is It Time for Total Neoadjuvant Therapy for Patients With Resectable Pancreatic Adenocarcinoma? J Oncol Pract. 2016;12(9):780-781. PMID: 27621327.

29.    Horwitz SM, Zelenetz AD, Gordon LI, et al. NCCN Guidelines Insights: Non-Hodgkin’s Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016;14(9):1067-1079. PMID: 27587620.

30.    Hu B, Arpag S, Zhang X, et al. Tuning PAK Activity to Rescue Abnormal Myelin Permeability in HNPP. PLoS Genet. 2016;12(9):e1006290. PMID: 27583434 PMCID: PMC5008806.

31.    Johnson SB, Soulos PR, Shafman TD, et al. Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy Versus Moderate Hypofractionation for Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;96(2S):E242. PMID: 27674157.

32.    Kachnic LA, Moughan J, Suntharalingam M, et al. Patient-Reported Outcomes (PROs) in NRG Oncology/RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Esophageal Cancer Treated Without Surgery. Int J Radiat Oncol Biol Phys. 2016;96(2S):S31. PMID: 27675900.

33.    Kelly KR, Gabrail N, Weitman S, et al. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. Cancer Chemother Pharmacol. 2016 PMID: 27638045.

34.    Kishan AU, Shaikh T, Wang J, et al. Clinical Outcomes for Patients With Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiation Therapy or Radical Prostatectomy: A Comparative Analysis. Int J Radiat Oncol Biol Phys. 2016;96(2S):E229. PMID: 27674120.

35.    Koutrouli N, Anagnostopoulos F, Tsikkinis A, Papastylianou D, Lepore S. Psychometric properties of the Greek version of the Social Constraints Scale in a sample of women with breast cancer. Women Health. 2016;56(4):413-427. PMID: 26496047.

36.    Kurland BF, Egleston BL. For Health-Related Quality of Life and Other Longitudinal Data, Analysis Should Distinguish Between Truncation by Death and Data Missing Because of Nonresponse. J Clin Oncol. 2016 PMID: 27601541.

37.    Lawrenson K, Kar S, McCue K, et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016;7:12675. PMID: 27601076 PMCID: PMC5023955.

38.    Leachman BK, Shaikh T, Li T, Anderson PR. Association Between Body Mass Index and Treatment Outcomes in Women Undergoing Breast Conservation: An Analysis of 3850 Women. Int J Radiat Oncol Biol Phys. 2016;96(2S):E59. PMID: 27675097.

39.    Ma CM, Eldib A, Chibani O, Mora G, Li J, Chen L. Exploring the Dosimetric Advantages of Cobalt Beams for Lung Cancer Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016;96(2S):E655-E656. PMID: 27675277.

40.    Maluchenko NV, Chang HW, Kozinova MT, et al. [Inhibiting the pro-tumor and transcription factor FACT: Mechanisms]. Mol Biol (Mosk). 2016;50(4):599-610. PMID: 27668600.

41.    Maluchenko NV, Chang HW, Kozinova MT, et al. Inhibiting the pro-tumor and transcription factor FACT: Mechanisms. Molecular Biology. 2016;50(4):532-541.

42.    Merza H, Sarkar R. Solitary extraosseous plasmacytoma. Clin Case Rep. 2016;4(9):851-854. PMID: 27648261 PMCID: PMC5018587.

43.    Meyer JE, Galloway TJ, Ruth K, et al. Efficacy of Pulsed Low-Dose-Rate Reirradiation: Results From a Phase 1 Clinical Trial. Int J Radiat Oncol Biol Phys. 2016;96(2S):S147. PMID: 27675641.

44.    Meyer LA, Cronin AM, Sun CC, et al. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 PMID: 27601552.

45.    Miron B, Ristau BT, Tomaszewski JJ, et al. Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer. Urol Case Rep. 2016;9:9-11. PMID: 27617213 PMCID: PMC5011172.

46.    Morgan RJ, Armstrong DK, Alvarez RD, et al. Ovarian Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network. 2016;14(9):1134-1163. WOS:000382903900009.

47.    Murphy CT, Handorf E, Sigurdson ER, et al. Assessment of National Practice Patterns of Radiation Therapy Use after Neoadjuvant Chemotherapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2016;96(2S):E51-E52. PMID: 27674882.

48.    Paly J, Shaikh T, Scott WJ, et al. Comparative Effectiveness of Standard Versus High-Dose Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016;96(2S):S200-S201. PMID: 27675778.

49.    Peri S, Caretti E, Tricarico R, et al. Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget. 2016 PMID: 27682873.

50.    Perrapato SD, Gore J, du Plessis M, et al. A Genomic Classifier Impacts Treatment Decision Making Among Patients With Biochemical Recurrence After Radical Prostatectomy: Results From the Multicenter Prospective PRO-IMPACT Study. Int J Radiat Oncol Biol Phys. 2016;96(2S):E222-E223. PMID: 27674104.

51.    Pishvaian M, Morse MA, McDevitt J, et al. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. Clin Colorectal Cancer. 2016 PMID: 27591895.

52.    Rahman R, Catalano PJ, Arvold ND, et al. Chemoradiation-Related Lymphopenia Is Common Among Glioblastoma Patients and Is Associated With Worse Progression-Free and Overall Survival. Int J Radiat Oncol Biol Phys. 2016;96(2S):E123. PMID: 27673836.

53.    Rall G, Knoll LJ. Development of Complex Models to Study Co- and Polymicrobial Infections and Diseases. PLoS Pathog. 2016;12(9):e1005858. PMID: 27607188 PMCID: PMC5015861.

54.    Ramos JD, Casey MF, Bamias A, et al. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin Appl Thromb Hemost. 2016 PMID: 27637910.

55.    Reese JB, Porter LS, Casale KE, et al. Adapting a couple-based intimacy enhancement intervention to breast cancer: A developmental study. Health Psychol. 2016;35(10):1085-1096. PMID: 27657981 PMCID: PMC5034713.

56.    Ristau BT, Geynisman DM. Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2016 PMID: 27638095.

57.    Shaikh T, Churilla TM, Murphy CT, Hallman MA, Scott WJ, Meyer JE. Comparative Effectiveness of Lobectomy, Sublobar Resection, and Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer: A Propensity-Matched Analysis. Int J Radiat Oncol Biol Phys. 2016;96(2S):E451-E452. PMID: 27674728.

58.    Shaikh T, Churilla TM, Zaorsky NG, et al. Postmastectomy Radiation Therapy in Women With ypN0-N3 Breast Cancer. Int J Radiat Oncol Biol Phys. 2016;96(2S):E27. PMID: 27674227.

59.    Shaikh T, Ruth K, Devarajan K, et al. Dosimetric and Clinical Predictors of Long-Term Toxicity in Patients Undergoing Hypofractionated Prostate Radiation Therapy: Results From a Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2016;96(2S):S123. PMID: 27675581.

60.    Sisti DA, Ramamurthy C. From alienism to ACOs: Integrating psychiatry, again. Psychiatric Services. 2016;67(4):372-374.

61.    Smith TM, McGovern K, Mojica A, Bhattacharya A. Hepatitis B virus immunity 15 years after vaccination: Implications for young adults. Consultant. 2016;56(9):796-798.

62.    Solomos AC, O’Regan KJ, Rall GF. CD4+ T cells require either B cells or CD8+ T cells to control spread and pathogenesis of a neurotropic infection. Virology. 2016;499:196-202. PMID: 27677156.

63.    Thomas C, Movva S. Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival. Onco Targets Ther. 2016;9:5619-5627. PMID: 27672333 PMCID: PMC5024770.

64.    Tricarico R, Kasela M, Mareni C, et al. Assessment of the InSiGHT Interpretation Criteria for the Clinical Classification of 24 MLH1 and MSH2 Gene Variants. Hum Mutat. 2016 PMID: 27629256.

65.    Wang EH, Abouassaly R, Yu JB, et al. Disparities in Access and Treatment of Patients With High-Risk Prostate Cancer: Results From a Population-Based Cohort. Int J Radiat Oncol Biol Phys. 2016;96(2S):E258. PMID: 27674195.

66.    Wang Y, Krais JJ, Bernhardy AJ, et al. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest. 2016;126(8):3145-3157. PMID: 27454289 PMCID: PMC4966309.

67.    Yao M, Zhang Q, Woods CR, et al. Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/RTOG 0129 and 0522. Int J Radiat Oncol Biol Phys. 2016;96(2S):S116-S117. PMID: 27675562.

68.    Yoon S, Shaikh T, Ross EA, et al. Patterns and Predictors of Failure Following Definitive Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2016;96(2S):E477-E478. PMID: 27674796.

69.    Yu J, Gong Y, Yuan L, et al. Investigation Into the Feasibility of Having Uniform Compliance Dosimetric Criteria Across Radiation Therapy Treatment Modalities for NRG Oncology/RTOG 0938 by Using Machine Learning. Int J Radiat Oncol Biol Phys. 2016;96(2S):E230-E231. PMID: 27674126.

70.    Zaorsky NG, Handorf E, Horwitz EM, Hallman MA, Smaldone MC. Pretreatment Predictors of Receiving Adjuvant Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;96(2S):E280. PMID: 27674259.

71.    Zaorsky NG, Ricco A, Churilla TM, Horwitz EM, Den RB. Applying ASTRO APEx Guidelines and RO-ILS to Medical Malpractice in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016;96(2S):E540. PMID: 27674964.

72.    Zhang Y, Xie J, Wang J, et al. Clinicopathological and Prognostic Analysis of Neuroendocrine Carcinoma of the Colorectum. Adv Clin Exp Med. 2016;25(4):719-724. PMID: 27629846.

73.    Zijoo R, von Mehren M. Efficacy of trabectedin for the treatment of liposarcoma. Expert Opin Pharmacother. 2016;17(14):1953-1962. PMID: 27615729.

Posted in databases, Library Resources, NCBI, News, websites

Looks like they’re updating their security protocol.

If you happened upon PubMed or any other NCBI database within the past couple of days, you may have noticed that they will be testing https on their web servers tomorrow between 8:00-9:00AM EDT. This may disrupt access to PubMed, Genome, Clinical Trials.gov, GenBank, OMIM, RefSeqGene, and other databases.

Posted in ejournals, Library Resources

The Cancer Letter

We have received word that some of our patrons are having trouble accessing The Cancer Letter. Please know that we have been working with our IT department, Serials Solutions (our online access manager), and the publisher for weeks (no exaggeration) to fix this issue, including investigating alternate routes of access such as passwords instead of IP recognition. In the meantime, if you are having trouble getting to  The Cancer Letter, try accessing it directly through the Library Web site instead of the Web link provided by the publisher in the email.

  1. Go to the Talbot Library home page.
  2. In the Quick Links box, located on the Library home page, click Cancer Letter, or
    Click Journal Holdings, type Cancer Letter in the text box provided, click Search, and then click Cancer Letter Publications.
  3. On The Cancer Letter home page click IP Log in.

Some things to keep in mind. If your computer is not on the Fox Chase network, you will be prompted to type in your FoxNet ID and password. As we hear of people who are being denied access because we suspect their IP is outside of the range, we ask the publisher to add the IP. Access to our subscription to The Cancer Letter is managed by Serials Solutions. They manage access to most all of our electronic journals. Any changes take a minimum of 24 hours to take effect.

Thank you for your patience and understanding and know that we are working to solve this problem.

 

Posted in Library Resources, Publications, scholarly literature

Staff Publications: August 2016

1.    Alcaraz KI, Sly J, Ashing K, et al. The ConNECT Framework: a model for advancing behavioral medicine science and practice to foster health equity. J Behav Med. 2016.

2.    Araiza-Olivera D, Chernoff J. HRAs helps hippo heterodimerize to evade tumor suppression. Small GTPases. 2016:0.

3.    Avkshtol V, Dong Y, Hayes SB, et al. A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer. Res Rep Urol. 2016;8:145-158.

4.    Beck TN, Georgopoulos R, Shagisultanova EI, et al. EGFR and RB1 as Dual Biomarkers in HPV-negative Head and Neck Cancer. Mol Cancer Ther. 2016.

5.    Beck TN, Golemis EA, Geynisman DM. Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al’s Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4. European Urology. 2016;70(3):E75-E76.

6.    Bradbury AR, Patrick-Miller L, Schwartz LA, et al. Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History. J Clin Oncol. 2016.

7.    Burt BM, Yao X, Shrager J, et al. Determinants of complete resection of thymoma by minimally invasive and open thymectomy: analysis of an international registry. J Thorac Oncol. 2016.

8.    Carlson RW, Scavone JL, Koh WJ, et al. NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care. J Natl Compr Canc Netw. 2016;14(8):961-969.
9.    Chu J, Li JG, Giannopoulos PF, et al. Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Abeta and tau neuropathology in the triple-transgenic mice. Mol Psychiatry. 2015;20(11):1329-1338.

10.    Coit DG, Thompson JA, Algazi A, et al. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016;14(8):945-958.

11.    Darlow S, Wen KY. Development testing of mobile health interventions for cancer patient self-management: A review. Health Informatics Journal. 2016;22(3):633-650.

12.    D’Souza JW, Hensley H, Doss M, et al. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-based Positron Emission Tomography Radiotracers. J Nucl Med. 2016.

13.    Fang M, Sigal LJ. Protective CD8+ T cell memory without help. Oncotarget. 2015;6(30):28529-28530.

14.    Ferguson SD, Xiu J, Weathers SP, et al. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016.

15.    Galloway TJ, Zhang QE, Nguyen-Tan PF, et al. Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. Int J Radiat Oncol Biol Phys. 2016.

16.    Gutowski CJ, Basu-Mallick A, Abraham JA. Management of Bone Sarcoma. Surg Clin North Am. 2016;96(5):1077-1106.

17.    Hall MJ, Obeid E, Daly MB. Multigene Panels to Evaluate Hereditary Cancer Risk: Reckless or Relevant? J Clin Oncol. 2016.

18.    Hoier H, Carrell HL, Gluskert JPs, Spears CP. Structure of ethyl phenyl selenone. Acta Crystallographica Section C: Crystal Structure Communications. 2016;49(3):520-523.

19.    Hoier H, Zacharias DE, Carrell HL, Gltjsker JPs. Structure of the molecular complex of anthracene with 1,8:4,5-naphthalenetetracarboxylic dianhydride. Acta Crystallographica Section C: Crystal Structure Communications. 2016;49(3):523-526.

20.    Ji W, Arnst C, Tipton AR, et al. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016;11(4):e0153518.

21.    Ji Y, Thomas C, Tulin N, et al. Charon Mediates Immune Deficiency-Driven PARP-1-Dependent Immune Responses in Drosophila. J Immunol. 2016.

22.    Layfield LJ, Roy-Chowdhuri S, Baloch Z, et al. Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. Diagn Cytopathol. 2016.

23.    Leachman BK, Galloway TJ. The Role for Radiation Therapy in the Management of Sarcoma. Surg Clin North Am. 2016;96(5):1127-1139.
24.    Li P, Lee E, Du F, et al. Nestin mediates hedgehog pathway tumorigenesis. Cancer Res. 2016.

25.    Melikechi N, Markushin Y, Connolly DC, Lasue J, Ewusi-Annan E, Makrogiannis S. Age-specific discrimination of blood plasma samples of healthy and ovarian cancer prone mice using laser-induced breakdown spectroscopy. Spectrochimica Acta – Part B Atomic Spectroscopy. 2016;123:33-41.

26.    Mitchell MA, Iannetta AA, Jennings MC, Fletcher MH, Wuest WM, Minbiole KP. Scaffold-Hopping of Multicationic Amphiphiles Yields Three New Classes of Antimicrobials. Chembiochem. 2015;16(16):2299-2303.

27.    Mukherjee S, Zhou G, Michel C, Voelz VA. Insights into Peptoid Helix Folding Cooperativity from an Improved Backbone Potential. J Phys Chem B. 2015;119(50):15407-15417.

28.    Nguyen MT, Weinberg DS. Biomarkers in Colorectal Cancer Screening. J Natl Compr Canc Netw. 2016;14(8):1033-1040.

29.    Parker D, Kutikov A, Uzzo RG, Smaldone MC. Understanding Chronic Kidney Disease of Surgical Versus Medical Origin: The Missing Link to the Partial Versus Radical Nephrectomy Debate? Eur Urol. 2015;68(6):1004-1006.

30.    Partridge AH, Hughes ME, Warner ET, et al. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016.

31.    Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015;68(6):959-967.

32.    Porpiglia AS, Farma JM. Current Treatment of Sarcomas. Surg Clin North Am. 2016;96(5):xv-xvi.

33.    Porpiglia AS, Reddy SS, Farma JM. Retroperitoneal Sarcomas. Surg Clin North Am. 2016;96(5):993-1001.

34.    Provenzale D, Gupta S, Ahnen DJ, et al. Genetic/familial high-risk assessment: Colorectal version 1.2016: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2016;14(8):1010-1030.

35.    Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016.

36.    Ristau BT, Kutikov A. Editorial Comment. J Urol. 2016.

37.    Samakai E, Hooper R, Martin KA, et al. Novel STIM1-dependent control of Ca2+ clearance regulates NFAT activity during T-cell activation. FASEB J. 2016.

38.    Scott EC, Hari P, Sharma M, et al. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016.

39.    Sheng JY, Movva S. Systemic Therapy for Advanced Soft Tissue Sarcoma. Surg Clin North Am. 2016;96(5):1141-1156.

40.    Solanki NR, Stadanlick JE, Zhang Y, et al. Rpl22 Loss Selectively Impairs alphabeta T Cell Development by Dysregulating Endoplasmic Reticulum Stress Signaling. J Immunol. 2016.

41.    Vijayvergia N, Boland PM, Handorf E, et al. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer. 2016;115(5):564-570.

42.    von Mehren M. Management of Gastrointestinal Stromal Tumors. Surg Clin North Am. 2016;96(5):1059-1075.

43.    Wang D, Braiteh F, Lee JJ, et al. Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016.

44.    Wang M, Pestov DG. Quantitative Northern Blot Analysis of Mammalian rRNA Processing. Methods Mol Biol. 2016;1455:147-157.

45.    Wiegers SE, Houser SR, Pearson HE, et al. A Metric-Based System for Evaluating the Productivity of Preclinical Faculty at an Academic Medical Center in the Era of Clinical and Translational Science. Clin Transl Sci. 2015;8(4):357-361.

46.    Zou ZW, Ma C, Medoro L, et al. LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. Oncotarget. 2016.

Posted in ejournals, Library Resources, Publications, scholarly literature

Staff Publications: July 2016

1.    Astsaturov I. The right and wrong of DOKing the nuclear receptor. EBioMedicine. 2016;8:7.

2.    Bashir B, Schneider D, Naglak MC, Churilla TM, Adelsberger M. Evaluation of prediction strategy and care coordination for COPD readmissions. Hosp Pract (1995). 2016;44(3):123-128.

3.    Beck TN, Korobeynikov VA, Kudinov AE, et al. Anti-Mullerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Rep. 2016;16(3):657-671.

4.    Beglyarova N, Banina E, Zhou Y, et al. Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC interactions as a target in pancreatic cancer. Clin Cancer Res. 2016.

5.    Ben-Ami E, Barysauskas CM, von Mehren M, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016.

6.    Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to Surgery and Breast Cancer Survival in the United States. JAMA Oncol. 2016;2(3):330-339.

7.    Cahn DB, Ristau BT, Uzzo RG, Smaldone MC. Editorial Comment. Urology. 2016.

8.    Chow LQ, Smith DC, Tan AR, et al. Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. Cancer Chemother Pharmacol. 2016;78(2):433-441.

9.    Collins BN, Nair US, Hovell MF, et al. Reducing Underserved Children’s Exposure to Tobacco Smoke: A Randomized Counseling Trial With Maternal Smokers. Am J Prev Med. 2015;49(4):534-544.

10.    Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016;34(23):2736-2742.

11.    Esselen KM, Cronin AM, Bixel K, et al. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016.

12.    Ettinger DS, Wood DE, Akerley W, et al. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016;14(7):825-836.

13.    Gerasimova NS, Studitsky VM. Hydroxyl radical footprinting of fluorescently labeled DNA. Moscow University Biological Sciences Bulletin. 2016;71(2):93-96.

14.    Geynisman DM, Wong YN. Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients? JAMA Oncol. 2016;2(3):295-296.

15.    Heckman C, Darlow S, Cohen-Filipic J, Kloss J. Mood Changes After Indoor Tanning Among College Women: Associations with Psychiatric/Addictive Symptoms. Health Psychol Res. 2016;4(1):5453.

16.    Igwe E, Woodburn J, Davolos J, et al. Patient perceptions and willingness to participate in clinical trials. Gynecol Oncol. 2016.

17.    Ito T, Derweesh IH, Ginzburg S, et al. Perioperative outcomes following partial nephrectomy performed on patients remaining on antiplatelet therapy. J Urol. 2016.

18.    Jenkins M, Patel S. Assessment of Risk Factors Associated with Nipple Reconstruction. Breast J. 2016;22(4):377-378.

19.    Ji Y, Tulin AV. Poly(ADP-ribosyl)ation of hnRNP A1 protein controls translational repression in Drosophila. Mol Cell Biol. 2016.

20.    Johnson SA, Zitserman D, Roegiers F. Numb regulates the balance between Notch recycling and late endosome targeting in Drosophila neural progenitor cells. Mol Biol Cell. 2016.

21.    Katz MH, Shi Q, Ahmad SA, et al. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016:e161137.

22.    Kishan AU, Shaikh T, Wang PC, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2016.

23.    Kurimchak AM, Shelton C, Duncan KE, et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep. 2016;16(5):1273-1286.

24.    Lee HO, Wang L, Kuo YM, et al. Lack of global epigenetic methylation defects in CBS deficient mice. J Inherit Metab Dis. 2016.

25.    Lukavsky R, Linkov G, Fundakowski C. A Novel Approach to Submandibular Gland Ptosis: Creation of a Platysma Muscle and Hyoid Bone Cradle. Arch Plast Surg. 2016;43(4):374-378.

26.    Manne SL, Myers-Virtue S, Kissane D, et al. Group-Based Trajectory Modeling of Fear of Disease Recurrence Among Women Recently Diagnosed with Gynecological Cancers. Psychooncology. 2016.

27.    Manne SL, Siegel SD, Heckman CJ, Kashy DA. A randomized clinical trial of a supportive versus a skill-based couple-focused group intervention for breast cancer patients. Journal of Consulting and Clinical Psychology. 2016;84(8):668-681.

28.    Mason WS, Gill US, Litwin S, et al. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology. 2016.

29.    McHugh M, Smaldone MC. Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors EDITORIAL COMMENTS. Journal of Urology. 2016;196(2):333-334.

30.    McKee KS, Seplaki C, Fisher S, Groth SW, Fernandez ID. Cumulative Physiologic Dysfunction and Pregnancy: Characterization and Association with Birth Outcomes. Matern Child Health J. 2016.

31.    Meng MB, Wang HH, Cui YL, et al. Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget. 2016.

32.    Moinpour CM, Unger JM, Ganz PA, et al. Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv. 2016.

33.    Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Ridge JA. Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research Reply. Journal of Clinical Oncology. 2016;34(19):2318-+.

34.    Najjar M, Saleh D, Zelic M, et al. RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4. Immunity. 2016;45(1):46-59.

35.    Narsinh KH, Van Buskirk M, Kennedy AS, et al. Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization. Radiology. 2016:152100.

36.    Nelson DB, Hanlon AL, Wu G, Liu C, Fredricks DN. First Trimester Levels of BV-Associated Bacteria and Risk of Miscarriage Among Women Early in Pregnancy. Matern Child Health J. 2015;19(12):2682-2687.

37.    Nelson DM, Jaber-Hijazi F, Cole JJ, et al. Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability. Genome Biol. 2016;17(1):158.

38.    Nogusa S, Slifker MJ, Ingram JP, Thapa RJ, Balachandran S. RIPK3 Is Largely Dispensable for RIG-I-Like Receptor- and Type I Interferon-Driven Transcriptional Responses to Influenza A Virus in Murine Fibroblasts. PLoS One. 2016;11(7):e0158774.

39.    Paice JA, Portenoy R, Lacchetti C, et al. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016.

40.    Pal SK, Agarwal N, Boorjian SA, et al. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol. 2016.

41.    Perales-Puchalt A, Svoronos N, Rutkowski MR, et al. FOLLICLE-STIMULATING HORMONE RECEPTOR IS EXPRESSED BY MOST OVARIAN CANCER SUBTYPES AND IS A SAFE AND EFFECTIVE IMMUNOTHERAPEUTIC TARGET. Clin Cancer Res. 2016.

42.    Peshkin BN, Kelly S, Nusbaum RH, et al. Patient perceptions of telephone vs. In-person BRCA1/BRCA2 genetic counseling. Journal of Genetic Counseling. 2016;25(3):472-482.

43.    Prudnikova TY, Chernoff J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases. 2016:1-6.

44.    Rajesh, Gao Z, Vishnubhotla R, et al. Genetically Engineered Antibody Functionalized Platinum Nanoparticles Modified CVD-Graphene Nanohybrid Transistor for the Detection of Breast Cancer Biomarker, HER3. Advanced Materials Interfaces. 2016.

45.    Rubin DJ, Handorf EA, Golden SH, Nelson DB, McDonnell ME, Zhao H. DEVELOPMENT AND VALIDATION OF A NOVEL TOOL TO PREDICT HOSPITAL READMISSION RISK AMONG PATIENTS WITH DIABETES. Endocr Pract. 2016.

46.    Shu CA, Pike MC, Jotwani AR, et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncol. 2016.

47.    Simon AJ, Lev A, Zhang Y, et al. Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects. J Exp Med. 2016;213(8):1429-1440.

48.    Su Y, Li J, Shi C, Hruban RH, Radice GL. N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN. Oncogene. 2016;35(25):3335-3341.

49.    van Vulpen M, Wang L. Within the next five years, adaptive hypofractionation will become the most common form of radiotherapy. Med Phys. 2016;43(7):3941.

50.    Vigorito E, Kuchenbaecker KB, Beesley J, et al. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One. 2016;11(7):e0158801.

51.    Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ, Dotan E. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer. 2016.

52.    Walker S, Wang C, Walradt T, et al. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood. 2016;127(7):948-951.

53.    Wei S, LiVolsi VA, Montone KT, Morrissette JJ, Baloch ZW. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience. Endocr Pathol. 2016.

54.    Yan H, Tammaro M, Liao S. Collision of trapped topoisomerase 2 with transcription and replication: Generation and repair of DNA double-strand breaks with 5ʹ adducts. Genes. 2016;7(7).

55.    Zaorsky NG, Ricco AG, Churilla TM, Horwitz EM, Den RB. ASTRO APEx(R) and RO-ILS are applicable to medical malpractice in radiation oncology. Future Oncol. 2016.

56.    Zeng C, Guo X, Long J, et al. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016;18(1):64.

57.    Zhang S, Xiao Q, Sherman SE, et al. Glycodendrimersomes from Sequence-Defined Janus Glycodendrimers Reveal High Activity and Sensor Capacity for the Agglutination by Natural Variants of Human Lectins. J Am Chem Soc. 2015;137(41):13334-13344.

58.    Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016.

59.    Zook P, Pathak HB, Belinsky M, et al. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor. Clin Cancer Res. 2016.

60.    Zucconi BE, Luef B, Xu W, et al. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112. Biochemistry. 2016;55(27):3727-3734.

Posted in Library Resources

Staff Publications: June 2016

Abdulghani J, Gokare P, Gallant JN, et al. Sorafenib and quinacrine target anti-apoptotic protein Mcl-1: a poor prognostic marker in anaplastic thyroid cancer (ATC). Clin Cancer Res. 2016.

Alolod GP, Traino HM, Siminoff LA. Utility and Usability of the Rapid Assessment of Hospital Procurement Barriers in Donation (RAPiD) as a Tool for OPO Hospital Development Staff. Prog Transplant. 2016.

Barta SK, Li H, Hochster HS, et al. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 2016.

Bass SB, Gordon TF, Gordon R, Parvanta C. Using eye tracking and gaze pattern analysis to test a “dirty bomb” decision aid in a pilot RCT in urban adults with limited literacy. BMC Med Inform Decis Mak. 2016;16(1):67.

Beitler JJ, Quon H, Jones CU, et al. ACR Appropriateness Criteria(R) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. Head Neck. 2016.

Cahn DB, Ristau BT, Ghiraldi EM, et al. Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology. 2016.

Chambers SK, Foley E, Clutton S, et al. The role of mindfulness in distress and quality of life for men with advanced prostate cancer. Qual Life Res. 2016.

Chang EI, Bradley JP. Reply: Additional Insights Regarding Virtual Surgical Planning for Osteocutaneous Free Flap Mandible Reconstruction. Plast Reconstr Surg. 2016.

Chwistek M, Ewerth N. Opioids and Chronic Pain in Cancer Survivors: Evolving Practice for Palliative Care Clinics. J Palliat Med. 2016;19(3):254.

Denlinger CS, Ligibel JA, Are M, et al. NCCN Guidelines Insights: Survivorship, Version 1.2016. J Natl Compr Canc Netw. 2016;14(6):715-724.

Devarajan K, Cheung VC. A Quasi-Likelihood Approach to Nonnegative Matrix Factorization. Neural Comput. 2016:1-31.

Duivenvoorden WC, Daneshmand S, Canter D, et al. Incidence, characteristics, and implications of thromboembolic events in patients with muscle-invasive urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy. J Urol. 2016.

Forman ME, Jennings MC, Wuest WM, Minbiole KP. Building a Better Quaternary Ammonium Compound (QAC): Branched Tetracationic Antiseptic Amphiphiles. ChemMedChem. 2016.

Franco-Barraza J, Beacham DA, Amatangelo MD, Cukierman E. Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts. Curr Protoc Cell Biol. 2016;71:10 19 11-10 19 34.

Gaponova AV, Nikonova A, Deneka AY, et al. A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC). Clin Cancer Res. 2016.

Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016.

Gor RA, Styskel BA, Li T, Canter DJ, Simhan J. Unexpected High Rates of Angiography and Angioembolization for Isolated Low Grade Renal Trauma: Results from a Large, Statewide, Trauma Database. Urology. 2016.

Jain R, Savage MJ, Forman AD, Mukherji R, Hall MJ. The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling? J Natl Compr Canc Netw. 2016;14(6):795-806.

Katz MH, Shi Q, Ahmad SA, et al. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016:e161137.

Kent T, Mateos-Gomez PA, Sfeir A, Pomerantz RT. Polymerase theta is a robust terminal transferase that oscillates between three different mechanisms during end-joining. Elife. 2016;5.

Kuang J, Li L, Guo L, et al. RNF8 promotes epithelial-mesenchymal transition of breast cancer cells. J Exp Clin Cancer Res. 2016;35(1):88.

Kudinov AE, Deneka A, Nikonova AS, et al. Musashi-2 (MSI2) supports TGF-beta signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A. 2016;113(25):6955-6960.

Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016.

Lieberman D, Rex D, Kochman M, Tokar J. Diminutive Colon Polyps Reply. Clinical Gastroenterology and Hepatology. 2016;14(6):916-918.

Liu D, Plimack ER, Hoffman-Censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016.

Malouf GG, Su X, Zhang J, et al. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016.

Meeker CR, Geynisman DM, Egleston BL, et al. Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract. 2016.

Miller-Halegoua S, Bowen DJ, Diefenbach MA, Tercyak KP. Creating the future of translational behavioral medicine. Transl Behav Med. 2016;6(2):167-168.

Monteith JA, Mellert H, Sammons MA, et al. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. Mol Oncol. 2016.

Nicolas E, Golemis EA, Arora S. POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies. Gene. 2016;590(1):128-141.

Nogusa S, Thapa RJ, Dillon CP, et al. RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus. Cell Host Microbe. 2016.

Ohar JA, Cheung M, Talarchek J, et al. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Cancer Res. 2016;76(2):206-215.

Patel B, Patel J, Cho JH, et al. Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex. Oncogene. 2016;35(23):3027-3036.

Pilarski R, Daly M. The authors’ reply. JNCCN Journal of the National Comprehensive Cancer Network. 2016;14(5):1-li.

Renault AL, Lesueur F, Coulombe Y, et al. ABRAXAS (FAM175A) and breast cancer susceptibility: No evidence of association in the breast cancer family registry. PLoS ONE. 2016;11(6):3.

Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016.

Ruggieri DG, Bass SB. African-American Parents’ Knowledge and Perceptions About BMI Measurements, School-Based BMI Screening Programs, and BMI Report Cards: Results from a Qualitative Investigation and Implications for School-to-Parent Communication. J Racial Ethn Health Disparities. 2016;3(2):320-330.

Sariyer IK, Sariyer R, Otte J, Gordon J. Pur-Alpha Induces JCV Gene Expression and Viral Replication by Suppressing SRSF1 in Glial Cells. PLoS One. 2016;11(6):e0156819.

Schiech L. Tonsillar cancer: What nurses need to know. Nursing. 2016;46(7):36-44.

Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016.

Seki M, LaCanna R, Powers JC, et al. Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation. J Pharmacol Exp Ther. 2016.

Simonelli M, Zucali P, Santoro A, et al. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase 1 in patients with hepatocellular carcinoma. Ann Oncol. 2016.

Sykes SM. The identity crisis of Hif-1alpha in HSC biology. Blood. 2016;127(23):2782-2784.

Terry MB, Goldberg M, Schechter S, et al. Comparison of Clinical, Maternal, and Self Pubertal Assessments: Implications for Health Studies. Pediatrics. 2016.

Wang EH, Yu JB, Abouassally R, et al. Disparities in Treatment of Patients with High-Risk Prostate Cancer: Results From A Population-Based Cohort. Urology. 2016.

Wang X, Li M, Gao Y, et al. Rheb1-mTORC1 maintains macrophage differentiation and phagocytosis in mice. Exp Cell Res. 2016;344(2):219-228.

Wang Y, Bernhardy AJ, Cruz C, et al. The BRCA1-Δ11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin. Cancer Research. 2016;76(9):2778-2790.

Wang Y, Cai KQ, Smith ER, et al. Follicle Depletion Provides A Permissive Environment for Ovarian Carcinogenesis. Mol Cell Biol. 2016.

Warner SG, Haddad D, Au J, et al. Oncolytic herpes simplex virus kills stem-like tumor-initiating colon cancer cells. Mol Ther Oncolytics. 2016;3:16013.

Xie L, Gu Y, Wen M, et al. Hydrogen sulfide induces keap1 S-sulfhydration and suppresses diabetes-accelerated atherosclerosis via Nrf2 activation. Diabetes. 2016.

Zaorsky NG, Egleston BL, Horwitz EM, et al. The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. Am J Clin Oncol. 2016.

Zaorsky NG, Shaikh T, Murphy CT, et al. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev. 2016;48:50-60.

Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives. J Control Release. 2016.

Zhao S, Teijaro C, Chen H, et al. Concise Syntheses of Bis-Strychnos Alkaloids (-)-Sungucine, (-)-Isosungucine, and (-)-Strychnogucine B from (-)-Strychnine. Chemistry. 2016.

Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy. 2016;8(7):785-798.

Zong JC, Heaggans SY, Long SY, et al. Detection of quiescent infections with multiple elephant endotheliotropic herpesviruses (EEHVs), including EEHV2, EEHV3, EEHV6, and EEHV7, within lymphoid lung nodules or lung and spleen tissue samples from five asymptomatic adult African elephants. Journal of Virology. 2016;90(6):3028-3043.